Article
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature - 8 Feb 2018
Hyman David M, Piha-Paul Sarina A, Won Helen, Rodon Jordi, Saura Cristina, Shapiro Geoffrey I, Juric Dejan, Quinn David I, Moreno Victor, Doger Bernard, Mayer Ingrid A, Boni Valentina, Calvo Emiliano, Loi Sherene, Lockhart Albert C, Erinjeri Joseph P, Scaltriti Maurizio, Ulaner Gary A, Patel Juber, Tang Jiabin, Beer Hannah, Selcuklu S Duygu, Hanrahan Aphrothiti J, Bouvier Nancy, Melcer Myra, Murali Rajmohan, Schram Alison M, Smyth Lillian M, Jhaveri Komal, Li Bob T, Drilon Alexander, Harding James J, Iyer Gopa, Taylor Barry S, Berger Michael F, Cutler Richard E, Xu Feng, Butturini Anna, Eli Lisa D, Mann Grace, Farrell Cynthia, Lalani Alshad S, Bryce Richard P, Arteaga Carlos L, Meric-Bernstam Funda, Baselga José, Solit David B
Abstract excerpt
Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.